character
human
bloodassoci
viral
commun
also
call
blood
virom
essenti
epidemiolog
surveil
anticip
new
potenti
threat
blood
transfus
safeti
current
risk
bloodborn
agent
transmiss
wellknown
virus
hbv
hcv
hiv
htlv
consid
control
highresourc
countri
howev
virus
unknown
unsuspect
may
transmit
recipi
bloodderiv
product
particularli
relev
consid
signific
proport
transfus
patient
immunocompromis
frequent
subject
fatal
outcom
sever
measur
prevent
transfus
transmiss
unknown
virus
implement
includ
exclus
atrisk
donor
leukocyt
reduct
donor
blood
physicochem
treatment
differ
blood
compon
howev
univers
method
pathogen
inactiv
would
applic
type
blood
compon
equal
effect
viral
famili
addit
among
avail
inactiv
procedur
viral
genom
recogn
less
effect
nonenvelop
virus
inadequ
inactiv
higher
viral
titer
plasma
pool
deriv
given
need
implement
new
methodolog
discoveri
unknown
virus
may
affect
blood
transfus
viral
metagenom
combin
high
throughput
sequenc
appear
promis
approach
identif
global
surveil
new
andor
unexpect
virus
could
impair
blood
transfus
safeti
le
risqu
transfusionnel
infectieux
aux
viru
connu
vhb
vhc
vih
et
htlv
peut
ce
jour
comm
en
raison
de
mesur
prise
par
la
plupart
de
pay
ressourc
en
revanch
le
risqu
potentiel
persist
est
dagent
infectieux
et
en
particuli
viraux
non
encor
ceci
est
dautant
plu
import
quun
proport
signif
de
patient
sont
et
donc
plu
de
form
infectieus
grave
dont
lissu
peut
fatal
plusieur
mesur
visant
la
transmiss
par
transfus
de
viru
inconnu
sont
mise
en
oeuvr
tel
que
lexclus
de
donneur
risqu
la
de
plasma
et
le
traitement
physicochimiqu
de
compos
sanguin
cepend
il
nexist
pa
ce
jour
de
universel
pour
linactiv
de
qui
soit
applic
tou
le
type
de
compos
sanguin
et
tout
aussi
efficac
pour
tout
le
famil
viral
par
ailleur
parmi
le
dinactiv
de
viraux
dispon
certain
dentr
ell
sont
reconnu
pour
moin
efficac
sur
le
viru
non
correspond
author
email
address
vsauvag
intsfr
v
sauvag
http
elsevi
masson
sa
right
reserv
v
sauvag
eloit
transfus
cliniqu
et
biologiqu
et
non
optimal
pour
inactiv
de
titr
viraux
dan
le
pool
de
plasma
ou
le
produit
il
donc
indispens
de
mettr
en
place
de
nouveaux
outil
pour
la
dagent
viraux
inconnu
suscept
daffect
la
infectieus
du
receveur
la
viral
au
haut
constitu
une
approch
prometteus
pour
lidentif
et
la
surveil
dagent
viraux
nouveaux
ou
inattendu
qui
pourraient
compromettr
la
transfusionnel
develop
countri
blood
organ
donor
routin
screen
rang
bloodborn
virus
hiv
hbv
hcv
htlv
countri
highli
sensit
screen
test
dramat
improv
safeti
blood
suppli
howev
transmiss
transfus
unknown
unsuspect
virus
respons
persist
asymptomat
viremia
remain
continu
threat
particularli
relev
consid
signific
proport
transfus
patient
immunocompromis
frequent
subject
fatal
outcom
sever
measur
prevent
transfus
transmiss
unknown
virus
implement
includ
exclus
atrisk
donor
leukocyt
reduct
donor
blood
physicochem
treatment
differ
blood
compon
aim
inactiv
infecti
agent
potenti
present
blood
howev
univers
method
pathogen
inactiv
would
applic
type
blood
compon
current
method
applic
red
blood
cell
concentr
equal
effect
viral
famili
sever
inactiv
procedur
avail
recogn
less
effect
nonenvelop
virus
human
parvoviru
v
hepat
hav
hepat
e
hev
virus
moreov
recent
public
also
confirm
viral
reduct
method
solventdeterg
heat
treatment
inadequ
inactiv
high
virem
titer
virus
plasma
pool
deriv
given
threat
blood
safeti
due
emerg
virus
crucial
import
thu
remain
imper
improv
blood
product
safeti
surveil
wellcharacter
viral
pathogen
hbv
hcv
hiv
v
also
implement
new
methodolog
discoveri
unknown
virus
may
affect
blood
transfus
safeti
record
emerg
infecti
diseas
risen
significantli
sinc
last
three
decad
period
year
emerg
infecti
diseas
pathogen
combin
report
emerg
infecti
diseas
eid
domin
zoonos
major
wildlif
origin
increas
ongo
document
novel
anim
virus
identifi
worldwid
predict
addit
anim
pathogen
may
jump
speci
barrier
potenti
becom
novel
human
infecti
diseas
near
futur
perhap
highli
pathogen
virus
account
eid
pathogen
class
like
emerg
estim
number
undiscov
mammalian
virus
least
estim
suggest
zoonot
eid
repres
seriou
threat
human
health
emphas
import
evalu
factor
involv
contact
human
anim
respons
emerg
zoonotichuman
infect
increas
contact
human
wildlif
habitat
mainli
due
agricultur
practic
global
travel
trade
import
factor
includ
climat
chang
promot
vector
expans
mosquito
tick
mass
human
migrat
due
war
natur
disast
poverti
desertif
reason
clear
increas
risk
arboviru
emerg
futur
due
environment
climat
chang
extens
tropic
urban
colon
expand
habitat
highli
anthropophil
mosquito
ie
chikungunya
dengu
virus
transmit
aed
aegypti
date
dengu
virus
intern
recogn
exist
threat
blood
safeti
due
known
transfusiontransmiss
severefat
diseas
recipi
arbovirus
potenti
transmiss
transfus
due
capac
induc
asymptomat
virem
phase
repres
new
risk
blood
safeti
last
year
broad
sensit
high
throughput
techniqu
base
metagenom
develop
detect
character
previous
unknown
variant
virus
associ
sever
human
diseas
method
base
random
amplif
genom
includ
panvir
microarray
high
throughput
sequenc
ht
overcom
convent
method
viral
identif
metagenom
give
access
nucleic
acid
present
given
sampl
allow
descript
viral
commun
divers
environment
human
anim
sampl
use
ht
metagenom
sequenc
also
demonstr
use
investig
infecti
diseas
unknown
etiolog
report
human
merkel
cell
carcinoma
polyomaviru
identifi
respons
thrombocytopenia
leukopenia
syndrom
china
associ
new
bunyaviru
acut
hemorrhag
fever
outbreak
uganda
central
africa
due
new
ebola
viru
rhabdoviru
respect
approach
also
use
identifi
novel
virus
respons
sever
fatal
posttranspl
associ
diseas
graft
recipi
besid
develop
metagenom
diagnost
tool
clinic
virolog
methodolog
appli
viral
safeti
biotechnolog
biolog
product
use
metagenom
possibl
provid
manufactur
exhaust
viral
bioburden
raw
materi
detect
adventiti
virus
liveattenu
vaccin
million
blood
compon
transfus
annual
franc
alon
viral
metagenom
appear
promis
approach
identif
global
surveil
new
andor
emerg
virus
could
impair
blood
transfus
safeti
metagenom
sequenc
offer
consider
advantag
compar
tradit
method
pathogen
identif
molecular
approach
abl
detect
simultan
multipl
organ
complex
sampl
without
cultur
priori
knowledg
microrgan
nucleic
acid
sequenc
howev
applic
viral
metagenom
clinic
sampl
made
difficult
fact
viral
sequenc
repres
low
proport
compar
host
dna
sequenc
transcript
bacteri
contamin
genet
materi
eg
environ
reagent
lead
requir
high
depth
sequenc
intens
bioinformat
analys
increas
probabl
viru
detect
despit
fact
amplif
method
librari
construct
sequenc
platform
impact
metagenom
composit
adequ
sampl
prepar
enhanc
ratio
viral
host
nucleic
acid
load
remain
crucial
step
biolog
sampl
pipelin
present
compris
key
step
recommend
viral
metagenom
analys
especi
appli
plasma
serum
sampl
fig
order
increas
proport
virus
differ
purif
enrich
strategi
appli
plasma
sampl
prior
sequenc
clear
centrifug
low
speed
membran
filtrat
andor
filter
ultracentrifug
polyethylen
glycol
peg
viru
precipit
digest
host
cellfre
dnarna
nucleas
treatment
remov
ribosom
rna
differ
techniqu
may
combin
maxim
amount
viral
nucleic
acid
extract
viral
metagenom
studi
agre
fact
nucleas
pretreat
biolog
sampl
essenti
step
importantli
reduc
amount
background
nucleic
acid
differ
manual
autom
method
extract
viral
nucleic
acid
use
fig
requir
choos
extract
dna
rna
simultan
independ
sinc
emerg
viral
threat
mainli
caus
rna
virus
viral
nucleic
acid
isol
perform
use
trizol
ls
life
technolog
reagent
design
obtain
high
qualiti
rna
molecul
high
yield
follow
viral
particl
lysi
nucleic
acid
precipit
step
viral
genom
rna
purifi
use
spin
column
residu
host
andor
viral
dna
remov
addit
dnase
digest
perform
directli
silica
membran
final
eluat
protocol
unwant
ribosom
rna
also
remov
rna
purif
remov
ribosom
rna
stage
captur
probe
hybrid
may
caus
viral
sequenc
loss
especi
unknown
virus
addit
trizol
extract
method
offer
possibl
recov
dna
viru
genom
organ
phase
nucleic
acid
extract
rna
convert
singlestrand
complementari
dna
ss
cdna
randomli
amplifi
togeth
dna
dna
rna
extract
simultan
obtain
concentr
requir
librari
construct
g
ng
depend
librari
prepar
kit
sequenc
platform
number
sequenceindepend
amplif
method
develop
use
combin
ht
viru
discoveri
common
sequenceindepend
singleprim
amplif
sispa
multipl
displac
amplif
mda
cdna
amplifi
fragment
length
polymorph
cdnaaflp
three
methodolog
amplifi
simultan
cdna
dna
linear
circular
singleand
doublestrand
viral
genom
sampl
sispa
method
extens
use
number
laboratori
world
allow
identif
mani
new
virus
anim
human
clinic
sampl
last
ten
year
compar
sispa
mda
use
bacteriophag
polymeras
mda
process
present
disadvantag
preferenti
amplifi
circular
ss
dna
linear
viral
genom
therebi
introduc
bia
amplif
howev
limit
prevent
detect
known
rna
virus
even
low
concentr
around
copiesml
discoveri
new
one
biolog
sampl
recent
mda
success
use
combin
ht
discov
novel
human
astroviru
associ
case
progress
enceph
boy
xlink
agammaglobulinemia
cdnaaflp
method
develop
bachem
et
al
adapt
viru
discoveri
vidisca
method
van
der
hoek
et
al
success
identif
novel
human
coronaviru
child
suffer
bronchiol
conjunct
later
vidisca
use
discov
novel
parvovirus
papillomaviru
veterinari
clinic
human
sampl
respect
despit
effici
nucleas
pretreat
decreas
host
background
signific
proport
read
deep
sequenc
alway
correspond
host
genom
transcript
increas
sensit
viru
detect
requir
clinic
applic
sever
method
develop
select
hybrid
amplifi
nonhuman
sequenc
virom
captur
sequenc
platform
vertebr
virus
vircapseqvert
compris
around
million
probe
cover
viral
taxa
known
infect
vertebr
preferenti
amplif
pathogen
sequenc
pathseq
base
oligonucleotid
match
abund
human
transcript
modifi
vidisca
method
use
random
hexam
anneal
rrna
today
vircapseqvert
combin
illumina
hiseq
appear
sensit
method
enabl
detect
west
nile
viru
genom
enteroviru
concentr
correspond
copiesml
respect
human
blood
serum
sampl
furthermor
accord
author
method
detect
viru
whose
genom
differ
probe
sequenc
make
method
suitabl
tool
viral
discoveri
howev
method
extrem
timeconsum
hybrid
step
h
therefor
nonappropri
clinic
diagnost
applic
final
particular
precaut
avoid
contamin
sampl
nucleic
acid
extract
amplif
product
exogen
nucleic
acid
must
implement
throughout
process
includ
ultraviolet
light
treatment
kit
reagent
substitut
commerci
carrier
rna
kit
neutral
chemic
carrier
linear
polyacrylamid
lpa
good
laboratori
practic
complianc
follow
revers
transcript
amplif
step
result
ds
dna
shear
defin
dna
fragment
size
accord
sequenc
platform
use
enzymat
eg
illumina
nextera
technolog
mechan
techniqu
eg
ultrason
fragment
bioruptor
diagenod
covari
covari
system
extrem
fragment
dna
endrepair
mechan
shear
ligat
specif
sequenc
adapt
barcod
allow
multiplex
sever
sampl
sequenc
run
adapterlig
dna
size
purifi
eg
agencourt
ampur
xp
bead
beckman
coulter
select
properli
ligat
dna
recondit
step
correspond
cycl
amplif
cycl
accord
sequenc
chemistri
perform
adaptormedi
amplif
step
use
increas
product
yield
enrich
dna
fragment
appropri
adapt
combin
optim
sequenc
fig
librari
quantifi
fluorimetricbas
method
eg
qubit
life
technolog
quantit
realtim
pcr
qualiti
control
bioanalyz
agil
technolog
confirm
librari
size
note
choic
librari
prepar
method
depend
part
input
dna
amount
exampl
illumina
truseq
dna
pcrfree
librari
prepar
kit
base
mechan
fragment
requir
g
input
dna
illumina
nextera
technolog
use
ng
dna
ion
torrent
technolog
librari
prepar
kit
base
enzymat
shear
ion
xpress
life
technolog
requir
minimum
ng
recent
develop
librari
prepar
kit
eg
illumina
nextera
xt
dna
low
input
dna
ng
nonamplifi
ds
dna
directli
fragment
associ
adapt
pcr
amplifi
obtain
requir
dna
concentr
sequenc
remov
nonspecif
preamplif
step
significantli
reduc
duplic
sequenc
thu
increas
genom
coverag
number
virus
detect
likewis
linkeramplifi
la
protocol
combin
optim
sampl
prepar
virus
enabl
detect
viral
sequenc
pg
input
dna
even
recommend
manufactur
result
librari
sequenc
follow
manufactur
protocol
sequenc
platform
novel
sequenc
technolog
current
avail
compris
secondand
thirdsingl
molecul
gener
sequenc
secondgener
sequenc
current
wide
use
includ
genom
analyz
ga
hiseqnextseqmiseq
illumina
gs
flx
systemg
junior
roch
whose
market
stop
ion
person
genom
machin
pgm
ion
proton
ion
torrent
life
technolog
tabl
note
ion
torrent
recent
launch
septemb
newest
sequenc
ion
instrument
tabl
offer
uniqu
devic
chip
output
number
read
read
length
compar
ion
pgm
ion
proton
eg
chip
system
similar
chip
pgm
pi
chip
proton
respect
secondgener
platform
present
distinct
sequenc
chemistri
detect
technolog
sequenc
workflow
base
librari
amplif
produc
clonal
cluster
sequenc
use
massiv
parallel
synthesi
fig
hand
given
number
secondgener
sequenc
sever
factor
must
consid
choic
technolog
includ
cost
perform
run
time
output
flexibl
conveni
type
applic
exampl
desktop
sequenc
illumina
miseq
ion
torrent
pgm
launch
posit
rapid
target
resequenc
whole
viral
bacteri
genom
sequenc
also
use
metagenom
analysi
offer
lower
depth
sequenc
million
read
per
run
miseq
million
read
ion
pgm
compar
illumina
hiseq
billion
pairend
read
ion
proton
million
read
ion
pi
chip
therefor
appropri
whole
metagenom
nowaday
number
scientif
public
use
hiseq
instrument
consider
higher
use
ion
proton
mainli
attribut
recent
avail
septemb
lower
capac
term
sampl
multiplex
ion
pii
chip
announc
need
confirm
increas
ion
proton
throughput
million
read
per
run
howev
ion
proton
much
afford
faster
compact
system
theoret
capabl
gener
long
read
announc
need
confirm
compar
hiseq
instrument
recent
platform
success
use
viral
metagenom
identifi
two
novel
papillomavirus
vagin
microbiom
hiv
posit
women
detect
differ
known
virus
plasma
sampl
spike
low
viral
concentr
date
use
third
gener
sequenc
viral
metagenom
remain
anecdot
thirdgener
sequenc
includ
singlemolecul
realtim
technolog
smrt
pacif
bioscienc
pacbio
rs
ii
tabl
featur
commonli
use
nextgener
sequenc
platform
research
clinic
diagnost
laboratori
system
nanopor
sequenc
technolog
oxford
nanopor
technolog
minion
promethion
devic
current
prereleas
test
minion
promethion
access
programm
compar
previou
gener
third
gener
character
absenc
templat
amplif
prior
sequenc
reason
also
call
singlemolecul
sequenc
signal
regist
realtim
abil
read
long
dna
fragment
sever
kilobas
although
obtain
long
read
revolutionari
platform
still
suffer
lower
accuraci
need
high
input
amount
dna
least
minion
devic
accord
experi
howev
newest
smrt
sequenc
sequel
system
announc
septembr
pacifc
bioscienc
may
provid
higher
accuraci
throughput
compar
pacbior
ii
continu
perform
improv
made
two
compani
secur
import
place
technolog
field
viral
metagenom
near
futur
lot
differ
pipelin
use
viral
metagenom
basic
read
first
trim
qualiti
often
least
illumina
technolog
duplic
ie
ident
read
suppress
second
step
read
filter
host
human
genom
high
stringenc
mean
principl
human
sequenc
remov
two
possibl
often
step
assembl
singl
read
contig
use
contig
allow
identifi
hit
distant
ident
would
distinguish
background
short
singl
read
read
new
gener
sequenc
becom
longer
longer
need
assembl
decreas
assembl
metagenom
read
contig
pose
specif
difficulti
due
uneven
abund
thu
coverag
viral
speci
moreov
random
amplif
also
lead
uneven
coverag
genom
combin
heterogen
increas
difficulti
assembl
see
discuss
tool
follow
step
conduct
blast
analysi
comprehens
databas
like
ncbi
nr
databas
identifi
sequenc
viru
best
hit
less
ressourc
demand
protocol
blast
first
viral
databas
like
ncbi
vrl
confirm
viral
best
hit
check
ncbi
nr
blast
analysi
done
singleton
also
read
assembl
contig
contig
non
assign
nucleotid
level
protein
blast
blastx
use
result
need
care
screen
virologist
practic
experi
metagenom
analysi
frequent
fals
posit
result
blast
conduct
high
evalu
coverag
put
viral
genom
good
criterion
assess
pertin
identif
new
viral
sequenc
second
possibl
map
read
databas
virus
use
stringent
rule
thu
identifi
known
virus
alreadi
present
databas
close
rel
type
pipelin
quicker
less
resourcedemand
particularli
well
suit
diagnost
first
comprehens
filter
demand
blast
analysi
see
exampl
comput
pipelin
surpi
viral
metagenom
associ
ht
success
demonstr
capac
detect
discov
virus
complex
biolog
sampl
serum
plasma
therefor
appear
promis
approach
identif
surveil
unknown
unexpect
virus
may
transmit
recipi
blood
product
assess
perform
limit
methodolog
recent
conduct
metagenom
analysi
plasmapool
sampl
collect
risk
subject
includ
recipi
multipl
blood
transfus
hbv
hcvand
hivinfect
blood
donor
larg
amount
variou
viral
sequenc
found
pool
among
anellovirus
human
pegiviru
hpgv
formerli
known
gb
viru
c
frequent
identifi
agent
presenc
hbv
dna
hcv
rna
confirm
plasma
pool
blood
donor
previous
found
hbv
hcv
infect
plasma
pool
hbv
dna
hcv
rna
account
iuml
iuml
respect
contrast
hiv
rna
account
copiesml
pool
detect
data
publish
also
detect
numer
short
nucleotid
sequenc
distantli
relat
viral
sequenc
report
current
databas
possibl
know
repres
bona
fide
virus
deriv
organ
despit
inclus
risk
individu
efficaci
pipelin
discov
new
virus
sequenc
suggest
new
viral
speci
identifi
plasma
sampl
analyz
studi
henc
find
confirm
viral
metagenom
combin
ht
abl
identifi
viral
divers
present
blood
sampl
also
highlight
difficulti
detect
low
level
viru
lower
equival
genomeml
time
studi
underlin
issu
includ
uncertainti
taxonom
assign
short
sequenc
reagent
contamin
instanc
retriev
sequenc
parvoviruslik
hybrid
genom
phvnihcqv
pool
although
initi
describ
possibl
new
caus
agent
seroneg
hepat
actual
found
background
contamin
water
elut
nucleic
acid
extract
silicabind
column
viral
contamin
spin
column
includ
circovirusesdensovirus
iridovirus
also
previous
report
togeth
find
demonstr
ht
result
must
interpret
caution
discoveri
new
viru
claim
interestingli
laupouicheung
et
al
report
xxviith
nation
congress
french
societi
blood
transfus
detect
human
sequenc
transfus
plasma
human
astrovirus
known
import
agent
viral
gastroenter
especi
young
children
elderli
immunocompromis
individu
human
initi
discov
diarrheal
stool
children
india
unit
state
sinc
detect
plasma
febril
child
suggest
may
spread
gastrointestin
tract
tissu
via
bloodstream
sever
recent
studi
report
potenti
associ
new
clade
astrovirus
neurolog
diseas
especi
enceph
case
anim
immunocompromis
individu
human
latest
report
case
concern
boy
xlink
agammaglobulinemia
associ
progress
global
motor
declin
cerebellar
syndrom
epilepsi
found
infect
new
astroviru
strain
clade
report
astrovirusassoci
enceph
also
describ
allogen
hematopoiet
stem
cell
bone
marrow
transplant
recipi
exampl
clearli
demonstr
use
viral
metagenom
sequenc
diagnosi
unexpect
viral
infect
exampl
virus
recent
describ
human
blood
sampl
metagenom
ht
cite
human
hepegiviru
discov
posttransfus
serum
sampl
blood
recipi
diverg
gemycirculaviru
found
blood
donat
giant
blood
marseilleviru
gmb
discov
initi
pool
sampl
collect
asymptomat
blood
donor
south
franc
subsequ
found
pcr
studi
healthi
donor
posttransfus
sera
thalassemia
patient
howev
two
recent
studi
report
subject
respect
gmb
viral
dna
detect
pcr
human
plasma
sampl
analyz
investig
need
confirm
realiti
novel
viral
infect
human
potenti
pathogen
transfus
transmiss
despit
undeni
analyt
strength
methodolog
investig
blood
virom
research
context
need
enforc
potenti
use
viral
metagenom
ht
discoveri
surveil
virus
concern
blood
safeti
unlik
first
occurr
emerg
infect
seen
transfus
recipi
paramount
import
implement
proactiv
surveil
emerg
viral
infect
blood
donor
popul
differ
part
world
especi
geograph
area
highest
rate
eid
identif
new
agent
process
evalu
transmiss
rout
blood
transfus
potenti
pathogen
accord
immun
statu
recipi
implement
moreov
risk
assess
help
defin
need
implement
new
prevent
strategi
reduc
transfus
transmiss
risk
associ
emerg
agent
project
gener
sever
recommend
help
health
author
issu
guidelin
approach
becom
part
blood
safeti
vigil
extend
address
gener
public
health
issu
regard
emerg
infecti
agent
vs
declar
compet
interest
cso
spin
institut
pasteur
pathoquest
dedic
diagnost
infecti
diseas
next
gener
sequenc
